

Iris Lansdorp-Vogelaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6911511/publications.pdf>

Version: 2024-02-01

171
papers

12,266
citations

41344

49
h-index

27406

106
g-index

174
all docs

174
docs citations

174
times ranked

11506
citing authors

#	ARTICLE	IF	CITATIONS
1	Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. <i>Gut</i> , 2023, 72, 101-108.	12.1	8
2	Risk-stratified strategies in population screening for colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 397-405.	5.1	25
3	Comparing Colorectal Cancer Screening Outcomes in the International Cancer Screening Network: A Consortium Proposal. <i>Gastroenterology</i> , 2022, 162, 668-674.	1.3	2
4	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 60-68.	8.1	42
5	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. <i>European Journal of Cancer</i> , 2022, 161, 38-43.	2.8	28
6	Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	15
7	Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland. <i>Preventive Medicine</i> , 2022, 157, 106990.	3.4	6
8	Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing. <i>PLoS ONE</i> , 2022, 17, e0264067.	2.5	11
9	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies. <i>Journal of Cancer Policy</i> , 2022, 32, 100328.	1.4	6
10	Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands. <i>Preventive Medicine Reports</i> , 2022, 27, 101791.	1.8	2
11	Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?. <i>MDM Policy and Practice</i> , 2022, 7, 238146832210970.	0.9	3
12	A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance. <i>PLoS ONE</i> , 2022, 17, e0267503.	2.5	0
13	Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 747-754.	8.1	40
14	Optimising colorectal cancer screening in Shanghai, China: a modelling study. <i>BMJ Open</i> , 2022, 12, e048156.	1.9	7
15	Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. <i>PLoS ONE</i> , 2022, 17, e0270223.	2.5	0
16	ADENOMA DETECTION RATE AND RISK OF INTERVAL POST-COLONOSCOPY COLORECTAL CANCER IN FIT-BASED SCREENING. <i>Gastrointestinal Endoscopy</i> , 2022, 95, AB82-AB83.	1.0	2
17	Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: A modelling study. <i>Preventive Medicine Reports</i> , 2022, 29, 101891.	1.8	2
18	Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. <i>Journal of Medical Screening</i> , 2021, 28, 268-276.	2.3	11

#	ARTICLE	IF	CITATIONS
19	Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1418-1425.	4.4	12
20	Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 547-555.	4.4	19
21	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. <i>Journal of the National Cancer Institute</i> , 2021, 113, 154-161.	6.3	46
22	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 208.	1.1	9
23	The impact of information about different absolute benefits and harms on intention to participate in colorectal cancer screening: A think-aloud study and online randomised experiment. <i>PLoS ONE</i> , 2021, 16, e0246991.	2.5	11
24	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 67.	2.0	2
25	Effects of cancer screening restart strategies after COVID-19 disruption. <i>British Journal of Cancer</i> , 2021, 124, 1516-1523.	6.4	55
26	Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. <i>International Journal of Cancer</i> , 2021, 149, 337-346.	5.1	8
27	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101735.	2.4	18
28	Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening. <i>Value in Health</i> , 2021, 24, 353-360.	0.3	5
29	Measures of longitudinal adherence to fecal-based colorectal cancer screening: Literature review and recommended approaches. <i>International Journal of Cancer</i> , 2021, 149, 316-326.	5.1	10
30	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 304-314.	8.1	99
31	Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1998.	7.4	145
32	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2021, 116, 1730-1733.	0.4	1
33	The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3531-3531.	1.6	0
34	The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. <i>Preventive Medicine Reports</i> , 2021, 22, 101392.	1.8	7
35	Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. <i>JAMA Oncology</i> , 2021, 7, 885.	7.1	5
36	Colorectal Cancer Screening in Young Adults. <i>Annals of Internal Medicine</i> , 2021, 174, 1039-1040.	3.9	4

#	ARTICLE	IF	CITATIONS
37	Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. PLoS ONE, 2021, 16, e0253893.	2.5	4
38	Colonoscopy and Its Complications are Inseparable of FIT-Based Screening. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
39	Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. Cancer Medicine, 2021, 10, 6835-6844.	2.8	2
40	The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. Preventive Medicine, 2021, 151, 106643.	3.4	32
41	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. MDM Policy and Practice, 2021, 6, 238146832098497.	0.9	4
42	Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. Alimentary Pharmacology and Therapeutics, 2021, 53, 1118-1125.	3.7	0
43	An Evolutionary Algorithm to Personalize Stool-Based Colorectal Cancer Screening. Frontiers in Physiology, 2021, 12, 718276.	2.8	1
44	Adherence to recommendations of Barrett's esophagus surveillance guidelines: a systematic review and meta-analysis. Endoscopy, 2020, 52, 17-28.	1.8	39
45	Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. Clinical Gastroenterology and Hepatology, 2020, 18, 1493-1500.	4.4	29
46	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. JNCI Cancer Spectrum, 2020, 4, pkz086.	2.9	39
47	Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. Clinical Gastroenterology and Hepatology, 2020, 18, 2760-2767.e12.	4.4	8
48	Cumulative Burden of Colorectal Cancer-associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
49	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cutoff level on yield of screening. International Journal of Cancer, 2020, 147, 1098-1106.	5.1	29
50	Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 10-21.	2.5	22
51	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. Clinical Gastroenterology and Hepatology, 2020, 18, 1961-1969.	4.4	15
52	Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. Journal of Medical Screening, 2020, 27, 68-76.	2.3	19
53	Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy – a nationwide survey. Endoscopy International Open, 2020, 08, E1405-E1413.	1.8	0
54	Intensity of Surveillance for Patients With Colorectal Adenomas. Annals of Internal Medicine, 2020, 172, 442.	3.9	0

#	ARTICLE	IF	CITATIONS
55	Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. Medical Decision Making, 2020, 40, 1034-1040.	2.4	7
56	Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era. Gastroenterology, 2020, 159, 1998-2003.	1.3	25
57	The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. American Journal of Gastroenterology, 2020, 115, 1026-1035.	0.4	1
58	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. European Journal of Cancer, 2020, 127, 224-235.	2.8	101
59	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of Clinical Medicine, 2020, 9, 190.	2.4	5
60	Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. Gut, 2019, 68, 873-881.	12.1	48
61	Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. BJU International, 2019, 123, 307-312.	2.5	13
62	Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections. Clinical Gastroenterology and Hepatology, 2019, 17, 2285-2293.	4.4	11
63	Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. The Lancet Gastroenterology and Hepatology, 2019, 4, 622-631.	8.1	27
64	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS ONE, 2019, 14, e0220234.	2.5	39
65	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ: British Medical Journal, 2019, 367, l5515.	2.3	122
66	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ: British Medical Journal, 2019, 367, l5383.	2.3	79
67	Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015. JAMA - Journal of the American Medical Association, 2019, 321, 1933.	7.4	58
68	Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut, 2019, 68, 1820-1826.	12.1	463
69	High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas. Annals of Internal Medicine, 2019, 171, 612.	3.9	18
70	Using Patient Preferences to Determine Noninferiority Margins in Trials. JAMA - Journal of the American Medical Association, 2019, 322, 2137.	7.4	0
71	Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme. The Lancet Gastroenterology and Hepatology, 2019, 4, 111-118.	8.1	10
72	Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program. Clinical Chemistry, 2019, 65, 419-426.	3.2	7

#	ARTICLE	IF	CITATIONS
73	Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs. <i>Radiology</i> , 2018, 287, 901-911.	7.3	40
74	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1737-1744.	2.8	11
75	Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. <i>Gastroenterology</i> , 2018, 154, 556-567.e18.	1.3	21
76	Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. <i>BMC Cancer</i> , 2018, 18, 464.	2.6	22
77	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 397-404.e2.	1.0	28
78	Stage distribution of screen-detected colorectal cancers in the Netherlands. <i>Gut</i> , 2018, 67, 1745-1746.	12.1	37
79	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	5.1	29
80	Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. <i>Gastroenterology</i> , 2018, 154, 105-116.e20.	1.3	26
81	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 158-164.	2.5	36
82	Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 504-512.e11.	4.4	36
83	Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. <i>Medical Decision Making</i> , 2018, 38, 917-929.	2.4	10
84	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2018, 155, 1392-1399.e5.	1.3	16
85	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. <i>PLoS ONE</i> , 2018, 13, e0202924.	2.5	7
86	Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. <i>Health Policy</i> , 2018, 122, 1206-1211.	3.0	11
87	Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. <i>Cancer</i> , 2018, 124, 2974-2985.	4.1	66
88	The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. <i>Cancer</i> , 2018, 124, 2964-2973.	4.1	157
89	Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. <i>Gut</i> , 2017, 66, 118-123.	12.1	24
90	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	4.4	20

#	ARTICLE	IF	CITATIONS
91	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1397-1404.e7.	4.4	51
92	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1328-1336.	2.5	14
93	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. <i>Gut</i> , 2017, 66, 1262-1267.	12.1	18
94	Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. <i>British Journal of Cancer</i> , 2017, 116, 44-49.	6.4	65
95	Colorectal cancer screening in Australia. <i>Lancet Public Health</i> , The, 2017, 2, e304-e305.	10.0	4
96	Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. <i>Gastroenterology</i> , 2017, 153, 1251-1259.e2.	1.3	45
97	Impact of adenoma detection on the benefit of faecal testing <i>vs</i>. colonoscopy for colorectal cancer. <i>International Journal of Cancer</i> , 2017, 141, 2359-2367.	5.1	6
98	Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. <i>United European Gastroenterology Journal</i> , 2017, 5, 448-454.	3.8	35
99	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. <i>BMC Cancer</i> , 2017, 17, 112.	2.6	8
100	Integrating personalised genomics into risk stratification models of population screening for colorectal cancer. <i>Australian and New Zealand Journal of Public Health</i> , 2017, 41, 3-4.	1.8	3
101	Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels. <i>Gastroenterology</i> , 2017, 152, 767-775.e2.	1.3	179
102	Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15-39 Years in Western Australia 1982-2007: Examination of Colonoscopy History. <i>Frontiers in Public Health</i> , 2017, 5, 179.	2.7	60
103	Optimizing Patient Risk Stratification for Colonoscopy Screening and Surveillance of Colorectal Cancer: The Role for Linked Data. <i>Frontiers in Public Health</i> , 2017, 5, 234.	2.7	3
104	Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries. <i>Health Affairs</i> , 2017, 36, 2151-2159.	5.2	16
105	Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. <i>PLoS ONE</i> , 2017, 12, e0172864.	2.5	40
106	Calibrating Parameters for Microsimulation Disease Models. <i>Medical Decision Making</i> , 2016, 36, 652-665.	2.4	9
107	Population-Based Colonoscopy Screening for Colorectal Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 894.	5.1	258
108	Rationale and design of the European Polyp Surveillance (EPoS) trials. <i>Endoscopy</i> , 2016, 48, 571-578.	1.8	90

#	ARTICLE	IF	CITATIONS
109	Developing a score chart to improve risk stratification of patients with colorectal adenoma. Endoscopy, 2016, 48, 563-570.	1.8	12
110	Cost effectiveness of surveillance for GI cancers. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 879-891.	2.4	6
111	Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program. Clinical Gastroenterology and Hepatology, 2016, 14, 1771-1777.	4.4	20
112	Nonbleeding adenomas: Evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectivenessâ€”A modeling study. Cancer, 2016, 122, 1680-1688.	4.1	22
113	Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clinical Gastroenterology and Hepatology, 2016, 14, 1445-1451.e8.	4.4	73
114	Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies. JAMA - Journal of the American Medical Association, 2016, 315, 2595.	7.4	388
115	Different modalities for colorectal cancer screening: experiences in The Netherlands so far. Colorectal Cancer, 2016, 5, 9-19.	0.8	2
116	Validation of Models Used to Inform Colorectal Cancer Screening Guidelines. Medical Decision Making, 2016, 36, 604-614.	2.4	52
117	Screening for gastric cancer in Western countries. Gut, 2016, 65, 543-544.	12.1	30
118	A restricted look at CRC screening: not considering annual stool testing as an option. American Journal of Managed Care, 2016, 22, e270-4.	1.1	0
119	The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Medical Decision Making, 2015, 35, 726-733.	2.4	6
120	Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. International Journal of Cancer, 2015, 136, 2864-2874.	5.1	17
121	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. Medical Care, 2015, 53, 630-638.	2.4	12
122	State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences. Cancer, 2015, 121, 3676-3683.	4.1	18
123	Optimal Colorectal Cancer Screening in States' Low-Income, Uninsured Populations-The Case of South Carolina. Health Services Research, 2015, 50, 768-789.	2.0	16
124	The impact of stratifying by family history in colorectal cancer screening programs. International Journal of Cancer, 2015, 137, 1119-1127.	5.1	8
125	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology, 2015, 149, 577-585.e4.	1.3	37
126	Colorectal cancer deaths attributable to nonuse of screening in the United States. Annals of Epidemiology, 2015, 25, 208-213.e1.	1.9	102

#	ARTICLE	IF	CITATIONS
127	Family history and the natural history of colorectal cancer: systematic review. <i>Genetics in Medicine</i> , 2015, 17, 702-712.	2.4	107
128	Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1464-1471.e4.	4.4	34
129	Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. <i>Gut</i> , 2015, 64, 1327-1337.	12.1	150
130	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2349.	7.4	72
131	Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. <i>Gut</i> , 2015, 64, 1584-1592.	12.1	79
132	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. <i>Cancer</i> , 2015, 121, 2281-2285.	4.1	180
133	Assessment of a cancer screening program. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 979-985.	2.4	18
134	The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. <i>Gut</i> , 2015, 64, 1985-1997.	12.1	58
135	Personalizing Colonoscopy Screening for Elderly Individuals Based on Screening History, Cancer Risk, and Comorbidity Status Could Increase Cost Effectiveness. <i>Gastroenterology</i> , 2015, 149, 1425-1437.	1.3	74
136	Utilization of Surveillance after Polypectomy in the Medicare Population – A Cohort Study. <i>PLoS ONE</i> , 2014, 9, e110937.	2.5	5
137	Optimising the expansion of the National Bowel Cancer Screening Program. <i>Medical Journal of Australia</i> , 2014, 201, 456-461.	1.7	39
138	A cost-effectiveness analysis of online, radio and print tobacco control advertisements targeting 25-39 year-old males. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 270-274.	1.8	15
139	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	2.5	61
140	The Appropriateness of More Intensive Colonoscopy Screening Than Recommended in Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2014, 174, 1568.	5.1	25
141	Should Colorectal Cancer Screening Be Considered in Elderly Persons Without Previous Screening?. <i>Annals of Internal Medicine</i> , 2014, 160, 750.	3.9	101
142	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. <i>Annals of Internal Medicine</i> , 2014, 161, 104.	3.9	123
143	Cost-effectiveness of screening and treating <i>Helicobacter pylori</i> for gastric cancer prevention. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 933-947.	2.4	58
144	Evaluation of New Technologies for Cancer Control Based on Population Trends in Disease Incidence and Mortality. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 117-123.	2.1	5

#	ARTICLE	IF	CITATIONS
145	Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. <i>Gut</i> , 2013, 62, 727-734.	12.1	68
146	Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 159, 667.	3.9	135
147	Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 728-736.	2.5	167
148	Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. <i>New England Journal of Medicine</i> , 2012, 366, 687-696.	27.0	2,553
149	Cost-effectiveness of Colorectal Cancer Screening. <i>Epidemiologic Reviews</i> , 2011, 33, 88-100.	3.5	246
150	Cost-effectiveness Analysis of a Quantitative Immunochemical Test for Colorectal Cancer Screening. <i>Gastroenterology</i> , 2011, 141, 1648-1655.e1.	1.3	111
151	Productivity Savings from Colorectal Cancer Prevention and Control Strategies. <i>American Journal of Preventive Medicine</i> , 2011, 41, e5-e14.	3.0	28
152	How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?. <i>Cancer</i> , 2011, 117, 4166-4174.	4.1	33
153	Radiation-Related Cancer Risks From CT Colonography Screening: A Risk-Benefit Analysis. <i>American Journal of Roentgenology</i> , 2011, 196, 816-823.	2.2	101
154	Comparative Economic Evaluation of Data from the ACRIN National CT Colonography Trial with Three Cancer Intervention and Surveillance Modeling Network Microsimulations. <i>Radiology</i> , 2011, 261, 487-498.	7.3	33
155	Clarifying Differences in Natural History between Models of Screening. <i>Medical Decision Making</i> , 2011, 31, 540-549.	2.4	45
156	A Systematic Comparison of Microsimulation Models of Colorectal Cancer. <i>Medical Decision Making</i> , 2011, 31, 530-539.	2.4	96
157	Fecal Occult Blood Testing When Colonoscopy Capacity is Limited. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1741-1751.	6.3	65
158	Sojourn Time of Preclinical Colorectal Cancer by Sex and Age: Estimates From the German National Screening Colonoscopy Database. <i>American Journal of Epidemiology</i> , 2011, 174, 1140-1146.	3.4	96
159	State Disparities in Colorectal Cancer Mortality Patterns in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1296-1302.	2.5	76
160	Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population. <i>Annals of Internal Medicine</i> , 2010, 153, 368.	3.9	73
161	Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. <i>Cancer</i> , 2010, 116, 544-573.	4.1	1,691
162	Cost-effectiveness of colorectal cancer screening - An overview. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 439-449.	2.4	55

#	ARTICLE	IF	CITATIONS
163	Cost-Effectiveness of Computed Tomographic Colonography Screening for Colorectal Cancer in the Medicare Population. Journal of the National Cancer Institute, 2010, 102, 1238-1252.	6.3	125
164	351: Post-Polypectomy Surveillance Practice of Adenoma Patients - Considerable Room for Improvement. Gastrointestinal Endoscopy, 2010, 71, AB115-AB116.	1.0	0
165	M1403: Perforation and Mortality of Colonoscopy - A Systematic Review. Gastrointestinal Endoscopy, 2010, 71, AB211-AB212.	1.0	0
166	Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer Screening. Journal of the National Cancer Institute, 2009, 101, 1412-1422.	6.3	167
167	At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. International Journal of Cancer, 2009, 124, 1161-1168.	5.1	61
168	Response to the letter to the editor by Hassan <i>et al.</i> : The diminutive lesion <i>versus</i> the advanced adenoma: Which is the real target of CT colonography screening?. International Journal of Cancer, 2009, 125, 1239-1240.	5.1	0
169	A novel hypothesis on the sensitivity of the fecal occult blood test. Cancer, 2009, 115, 2410-2419.	4.1	74
170	Individualizing colonoscopy screening by sex and race. Gastrointestinal Endoscopy, 2009, 70, 96-108.e24.	1.0	67
171	Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2008, 149, 659.	3.9	515